Ty Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Novo Nordisk ’s weight loss injection semaglutide—the active ingredient in Ozempic and Wegovy —for lowering the risk of cardiovascular events in adults with obesity, after research indicated the high-demand drug was beneficial in cutting the risk of strokes or heart attacks in patients whether they lose weight or not.The U.K.’s Medicines and Healthcare products Regulatory Agency made the approval—the first weight loss drug to be prescribed in the U.K.
About 6.5% of participants in the study—which included over 17,600 people—experienced cardiovascular events, compared to 8% who received a placebo, according to the study.Wegovy for preventing cardiovascular events in overweight or obese adults in the U.S. in March, citing findings from the same study, while noting the drug should be taken with a reduced calorie diet and increased physical activity.
Wegovy Novo Nordisk GLP-1 Semaglutide
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid ShortagesRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid ShortagesRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Novo Nordisk's Wegovy weight loss drug approved in ChinaNovo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management.
Read more »
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, OzempicThe new plant in Clayton, North Carolina, will be responsible for filling and packaging syringes and injection pens for Wegovy, Ozempic and other drugs.
Read more »
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, OzempicThe new plant in Clayton, North Carolina, will be responsible for filling and packaging syringes and injection pens for Wegovy, Ozempic and other drugs.
Read more »
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatmentThe U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.
Read more »